^
    3d
    The Efficacy of CDK4/6 Inhibitors as Late Therapy in Patients Treated with Palbociclib and Abemaciclib Two Sequentially (PubMed, Gan To Kagaku Ryoho)
    One PD and 6 adverse events were the reasons for switching to ABM after taking PLB. Although the number of patients was small, PFS with sequential CDK4/6 inhibitors could be expected to be longer than 6 months, suggesting that the treatment may be useful in extending the time to chemotherapy induction.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib)
    3d
    postMONARCH: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (clinicaltrials.gov)
    P3, N=368, Active, not recruiting, Eli Lilly and Company | Trial completion date: Feb 2026 --> Dec 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant
    4d
    Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial. (PubMed, Nat Med)
    ClinicalTrials.gov registration no. NCT02523014 .
    P2 data • Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NF2 (Neurofibromin 2)
    |
    Verzenio (abemaciclib)
    4d
    TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jun 2026 --> Jan 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane
    4d
    Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors. (PubMed, Sci Adv)
    Notably, genetic and pharmacologic inhibition of BAP1 markedly improves abemaciclib efficacy in multiple mouse models and patient-derived organoids (PDOs). These findings establish BAP1 as a key regulator of tumor plasticity and adaptive resistance through epigenetic reprogramming and suggest a promising strategy for overcoming adaptive therapeutic CDK4/6i resistance by targeting quiescent, drug-resistant cancer cells.
    Journal
    |
    BAP1 (BRCA1 Associated Protein 1) • TCF4 (Transcription Factor 4)
    |
    Verzenio (abemaciclib)
    4d
    Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies. (PubMed, Geburtshilfe Frauenheilkd)
    Eligible patients for ribociclib or abemaciclib therapy were retrospectively identified from 5053 early breast cancer cases at the university hospitals of Ulm, Lübeck and Tübingen, using the monarchE and NATALEE criteria. Despite its retrospective limitations, this analysis provides valuable insight into the impact of centralized care on travel time and CO 2 emissions for oral cancer therapies in Germany. As the use of oral therapies increases, clinicians, patients, policymakers and the pharmaceutical industry should jointly develop strategies to optimize the safety, feasibility, and efficacy of oral therapies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • Kisqali (ribociclib)
    5d
    Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib. (PubMed, Breast)
    Individual patient coaching based on MOAT
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Verzenio (abemaciclib)
    5d
    POETIC-A: PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (clinicaltrials.gov)
    P3, N=123, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting | N=2032 --> 123 | Trial completion date: Mar 2032 --> Oct 2030
    Enrollment closed • Enrollment change • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane
    5d
    Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, University of Washington | Trial completion date: Sep 2027 --> Jul 2026 | Trial primary completion date: Sep 2026 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Verzenio (abemaciclib)
    5d
    EVOLVE-BDT: Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (clinicaltrials.gov)
    P2, N=700, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P2 trial
    |
    Tempus xR
    |
    everolimus • capecitabine • Verzenio (abemaciclib)
    6d
    Dual Targeting of Tau Kinases and Autophagy by Abemaciclib Independent of CDK4/6 Inhibition. (PubMed, Adv Sci (Weinh))
    This dual modulation-suppression of tau phosphorylation and facilitation of degradation-highlights abemaciclib as a promising repurposed therapeutic for AD. Our findings establish a novel pharmacological profile for abemaciclib beyond its canonical role in cell cycle control, offering immediate translational potential for tau-targeted AD therapy.
    Journal
    |
    MAPT (Microtubule Associated Protein Tau)
    |
    Verzenio (abemaciclib)
    6d
    Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, University of Miami | Recruiting --> Active, not recruiting | N=500 --> 24
    Enrollment closed • Enrollment change • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • everolimus • tamoxifen • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • Truqap (capivasertib) • letrozole • anastrozole • exemestane • Orserdu (elacestrant) • Navelbine oral (vinorelbine tartrate oral)